Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2Plasma cell 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 635Glioblastoma 566Glioma 405Neuroblastoma 174Neoplasms 123Astrocytoma 106Central Nervous System Neoplasms 103Medulloblastoma 87Breast Neoplasms 86Meningioma 82Carcinoma, Non-Small-Cell Lung 78Melanoma 77Lung Neoplasms 69Sarcoma 66Ependymoma 64Neurofibromatosis 1 63Recurrence 50Oligodendroglioma 48Neoplasm Metastasis 48Osteosarcoma 47Meningeal Carcinomatosis 46Rhabdomyosarcoma 45Diffuse Intrinsic Pontine Glioma 44Pheochromocytoma 43Rhabdoid Tumor 41Paraganglioma 41Gliosarcoma 40Sarcoma, Ewing 39Pancreatic Neoplasms 39Colorectal Neoplasms 33

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vascular Neoplasms × CNS × 1 year × Clear all
NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡